Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE4
Total Enrollment
20000 participants
Study Classification
INTERVENTIONAL
Study Start Date
2003-03-31
Study Completion Date
2005-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The WHO has initiated a program to eliminate blinding trachoma by the year 2020, in large part by mass oral azithromycin distributions. It is not clear how frequently or for how long these treatments are necessary. Here we assess the frequency and duration of treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tripartite International Research for the Elimination of Trachoma
NCT01202331
Trachoma
Chlamydia
COMPLETED
PHASE4
Kebele Elimination of Trachoma for Ocular Health
NCT03335072
Trachoma
ACTIVE_NOT_RECRUITING
PHASE4
Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger
NCT00618449
Trachoma
Chlamydia Trachomatis
COMPLETED
PHASE4
Trachoma Amelioration in Northern Amhara (TANA)
NCT00322972
Trachoma
Chlamydia
COMPLETED
PHASE4
Water Uptake for Health in Amhara Pilot
NCT02373657
Trachoma
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
40 villages in the Gurage Zone of Ethiopia were randomly assigned to biannual treatment, annual treatment, and a single treatment. Each treatment consisted of a single dose of oral azithromycin to the entire population over the age of 1 year (when the study was started, azithromycin had not yet been approved for ages below 1 year). We assess the prevalence the ocular chlamydia that causes trachoma in the peak prevalence age of 1-5 years at baseline, and 2, 6, 12, 18, and 24 months post treatment. An extension of the study monitors infection at 30 and 36 months post treatment. Untreated villages from the same area are enrolled in a step-wedge design to assess the presence of a secular trend. A random sample of those not within the 1-5 year old age group are examined to assess the prevalence of infection in the entire community.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Trachoma
Chlamydia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mass treatment with oral azithromycin to an entire village
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Age 1 to 5 years old in a village in the Gurage zone with endemic trachoma
Exclusion Criteria
Refusal of village chief (for village inclusion), or refusal of parent or guardian (for individual inclusion)
Minimum Eligible Age
1 Year
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, San Francisco
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas M Lietman, MD
Role: PRINCIPAL_INVESTIGATOR
Proctor Foundation, UCSF
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ORBIS-Ethiopia
Addis Ababa, , Ethiopia
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Ethiopia
References
Explore related publications, articles, or registry entries linked to this study.
Melese M, Chidambaram JD, Alemayehu W, Lee DC, Yi EH, Cevallos V, Zhou Z, Donnellan C, Saidel M, Whitcher JP, Gaynor BD, Lietman TM. Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments. JAMA. 2004 Aug 11;292(6):721-5. doi: 10.1001/jama.292.6.721.
Reference Type
BACKGROUND
Chidambaram JD, Melese M, Alemayehu W, Yi E, Prabriputaloong T, Lee DC, Cevallos V, Zhou Z, Whitcher JP, Gaynor BD, Lietman TM. Mass antibiotic treatment and community protection in trachoma control programs. Clin Infect Dis. 2004 Nov 1;39(9):e95-7. doi: 10.1086/424747. Epub 2004 Oct 6.
Reference Type
BACKGROUND
Ray KJ, Porco TC, Hong KC, Lee DC, Alemayehu W, Melese M, Lakew T, Yi E, House J, Chidambaram JD, Whitcher JP, Gaynor BD, Lietman TM. A rationale for continuing mass antibiotic distributions for trachoma. BMC Infect Dis. 2007 Aug 7;7:91. doi: 10.1186/1471-2334-7-91.
Reference Type
BACKGROUND
Lee S, Alemayehu W, Melese M, Lakew T, Lee D, Yi E, Cevallos V, Donnellan C, Zhou Z, Chidambaram JD, Gaynor BD, Whitcher JP, Lietman TM. Chlamydia on children and flies after mass antibiotic treatment for trachoma. Am J Trop Med Hyg. 2007 Jan;76(1):129-31.
Reference Type
BACKGROUND
Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, House J, Cevallos V, Zhou Z, Maxey K, Lee DC, Shapiro BL, Srinivasan M, Porco T, Whitcher JP, Gaynor BD, Lietman TM. Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA. 2006 Mar 8;295(10):1142-6. doi: 10.1001/jama.295.10.1142.
Reference Type
BACKGROUND
Haug S, Lakew T, Habtemariam G, Alemayehu W, Cevallos V, Zhou Z, House J, Ray K, Porco T, Rutar T, Keenan J, Lietman TM, Gaynor BD. The decline of pneumococcal resistance after cessation of mass antibiotic distributions for trachoma. Clin Infect Dis. 2010 Sep 1;51(5):571-4. doi: 10.1086/655697.
Reference Type
BACKGROUND
Shah NA, House J, Lakew T, Alemayehu W, Halfpenny C, Hong KC, Keenan JD, Porco TC, Whitcher JP, Lietman TM, Gaynor BD. Travel and implications for the elimination of trachoma in ethiopia. Ophthalmic Epidemiol. 2010 Mar;17(2):113-7. doi: 10.3109/09286581003624921.
Reference Type
BACKGROUND
Keenan JD, Lakew T, Alemayehu W, Melese M, Porco TC, Yi E, House JI, Zhou Z, Ray KJ, Acharya NR, Whitcher JP, Gaynor BD, Lietman TM. Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma. Am J Trop Med Hyg. 2010 Mar;82(3):482-7. doi: 10.4269/ajtmh.2010.09-0315.
Reference Type
BACKGROUND
Biebesheimer JB, House J, Hong KC, Lakew T, Alemayehu W, Zhou Z, Moncada J, Roger A, Keenan J, Gaynor BD, Schachter J, Lietman TM. Complete local elimination of infectious trachoma from severely affected communities after six biannual mass azithromycin distributions. Ophthalmology. 2009 Nov;116(11):2047-50. doi: 10.1016/j.ophtha.2009.04.041. Epub 2009 Sep 10.
Reference Type
BACKGROUND
Lakew T, Alemayehu W, Melese M, Yi E, House JI, Hong KC, Zhou Z, Ray KJ, Porco TC, Gaynor BD, Lietman TM, Keenan JD. Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution. PLoS Negl Trop Dis. 2009 Aug 25;3(8):e507. doi: 10.1371/journal.pntd.0000507.
Reference Type
BACKGROUND
Lakew T, House J, Hong KC, Yi E, Alemayehu W, Melese M, Zhou Z, Ray K, Chin S, Romero E, Keenan J, Whitcher JP, Gaynor BD, Lietman TM. Reduction and return of infectious trachoma in severely affected communities in Ethiopia. PLoS Negl Trop Dis. 2009;3(2):e376. doi: 10.1371/journal.pntd.0000376. Epub 2009 Feb 3.
Reference Type
BACKGROUND
Hong KC, Schachter J, Moncada J, Zhou Z, House J, Lietman TM. Lack of macrolide resistance in Chlamydia trachomatis after mass azithromycin distributions for trachoma. Emerg Infect Dis. 2009 Jul;15(7):1088-90. doi: 10.3201/eid1507.081563.
Reference Type
BACKGROUND
Yang JL, Hong KC, Schachter J, Moncada J, Lekew T, House JI, Zhou Z, Neuwelt MD, Rutar T, Halfpenny C, Shah N, Whitcher JP, Lietman TM. Detection of Chlamydia trachomatis ocular infection in trachoma-endemic communities by rRNA amplification. Invest Ophthalmol Vis Sci. 2009 Jan;50(1):90-4. doi: 10.1167/iovs.08-2247. Epub 2008 Aug 8.
Reference Type
BACKGROUND
Melese M, Alemayehu W, Lakew T, Yi E, House J, Chidambaram JD, Zhou Z, Cevallos V, Ray K, Hong KC, Porco TC, Phan I, Zaidi A, Gaynor BD, Whitcher JP, Lietman TM. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA. 2008 Feb 20;299(7):778-84. doi: 10.1001/jama.299.7.778.
Reference Type
BACKGROUND
Gill DA, Lakew T, Alemayehu W, Melese M, Zhou Z, House JI, Hong KC, Ray KJ, Gandhi N, Whitcher JP, Gaynor BD, Lietman TM. Complete elimination is a difficult goal for trachoma programs in severely affected communities. Clin Infect Dis. 2008 Feb 15;46(4):564-6. doi: 10.1086/526777.
Reference Type
BACKGROUND
Keenan JD, Lakew T, Alemayehu W, Melese M, House JI, Acharya NR, Porco TC, Gaynor BD, Lietman TM. Slow resolution of clinically active trachoma following successful mass antibiotic treatments. Arch Ophthalmol. 2011 Apr;129(4):512-3. doi: 10.1001/archophthalmol.2011.46. No abstract available.
Reference Type
BACKGROUND
Cevallos V, Whitcher JP, Melese M, Alemayehu W, Yi E, Chidambaram JD, Lee S, Reddy H, Gaynor BD, Lietman TM, Keenan JD. Association of conjunctival bacterial infection and female sex in cicatricial trachoma. Invest Ophthalmol Vis Sci. 2012 Aug 7;53(9):5208-12. doi: 10.1167/iovs.12-9984.
Reference Type
DERIVED
See CW, Alemayehu W, Melese M, Zhou Z, Porco TC, Shiboski S, Gaynor BD, Eng J, Keenan JD, Lietman TM. How reliable are tests for trachoma?--a latent class approach. Invest Ophthalmol Vis Sci. 2011 Aug 3;52(9):6133-7. doi: 10.1167/iovs.11-7419.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-02630
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Nepal Elimination of Trachoma Study
NCT02176057
WITHDRAWN
PHASE2/PHASE3
Enhancing the A in SAFE for Trachoma
NCT05634759
COMPLETED
PHASE4
Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania
NCT00347607
COMPLETED
PHASE4
Effect of Intensive Fly Control on Trachoma and Ocular Chlamydia Infection in Tanzania
NCT00347763
COMPLETED
PHASE4
Community Health Azithromycin Trial in Burkina Faso
NCT03676764
COMPLETED
PHASE4
Sanitation, Water, and Instruction in Face-washing for Trachoma I/II
NCT02754583
COMPLETED
PHASE3
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
NCT01767506
COMPLETED
NA
Testing Insect Repellents Against Musca Sorbens, the Vector of Trachoma
NCT03813069
COMPLETED
PHASE2
Mortality Reduction After Oral Azithromycin: Mortality Study
NCT02047981
COMPLETED
PHASE4
Comparison of Two Different Doses of Azithromycin for Treatment of Yaws
NCT02344628
COMPLETED
PHASE3
Mortality Reduction After Oral Azithromycin: Morbidity Study
NCT02048007
COMPLETED
PHASE4
Azithromycin for Uncomplicated Severe Acute Malnutrition in Burkina Faso (Pilot)
NCT03568643
COMPLETED
PHASE3
Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin
NCT03570814
COMPLETED
PHASE4
Single Dose Azithromycin to Prevent Cholera in Children
NCT04326478
ACTIVE_NOT_RECRUITING
PHASE2
Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children
NCT02414399
ACTIVE_NOT_RECRUITING
PHASE4
Resiliency Through Azithromycin for Children (REACH), Côte d'Ivoire
NCT04617626
COMPLETED
NA
Intestinal Microbiome Post-Azythromycin/Albendazole Treatment
NCT03032042
WITHDRAWN
PHASE4
Azithromycin - Ivermectin Mass Drug Administration for Skin Disease
NCT02775617
COMPLETED
PHASE4
Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition
NCT06010719
RECRUITING
PHASE4
Improving Care Through Azithromycin Research for Infants in Africa
NCT04235816
ACTIVE_NOT_RECRUITING
PHASE3
Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition
NCT01395381
WITHDRAWN
NA
The Efficacy of Five Anthelmintic Regimes Against Trichuris Trichiura Infections in Schoolchildren in Jimma, Ethiopia
NCT01327469
COMPLETED
PHASE4
Single-dose Azithromycin for the Treatment of Yaws
NCT01382004
COMPLETED
PHASE3
Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )
NCT03676140
COMPLETED
PHASE3
Antibiotics for Children With Severe Diarrhoea
NCT03130114
COMPLETED
PHASE3